Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg and FUS in ALS
NCT07193953Phase 1Active, not recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Apr 2025
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of intravenous immunoglobulin G in amyotrophic lateral sclerosis (ALS), sponsored by Sunnybrook Health Sciences Centre. Primary endpoints: Safety of IVIg in patients with ALS at Week 24, Safety of DEFINITY microbubbles at Week 24 and 2 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07193953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193953.